secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0000950170-24-116847
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint doses first patient in Phase 3 LUGANO trial of DURAVYU for wet AMD; LUCIA trial by end 2024, topline 2026
--------------------------------------------------------------------------------

- First patient dosed in global Phase 3 LUGANO trial of DURAVYU (vorolanib) for wet AMD; non-inferiority design vs aflibercept.
- Second Phase 3 LUCIA trial first dosing expected by end of 2024; topline data anticipated in 2026.
- Trials enroll ~400 patients each; DURAVYU dosed every 6 months vs on-label aflibercept every 2 months, after 3 loading doses.
- Over 190 patients previously treated in DAVIO/DAVIO 2; favorable safety; treatment-naïve and treatment-experienced included.
- Re-dosing evaluated in both trials; primary endpoint: average change in BCVA at weeks 52 and 56 vs baseline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024116847/0000950170-24-116847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024116847/eypt-20241022.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-116847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer